Journal of Immunology Research
Volume 2017 (2017), Article ID 7304658, 8 pages
https://doi.org/10.1155/2017/7304658
Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies
1Institute of Clinical Immunology and Allergology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
2Department of Mathematics, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
34th Department of Internal Medicine-Haematology, Faculty of Medicine, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
4Department of Clinical Immunology and Allergy, Faculty of Medicine, Masaryk University, St. Anne‘s University Hospital, Brno, Czech Republic
5RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic
Correspondence should be addressed to P. Kralickova; zc.khnf@avokcilark.anilvap
Received 18 April 2017; Revised 27 July 2017; Accepted 7 September 2017; Published 17 December 2017
Academic Editor: Senthami R. Selvan
Copyright © 2017 P. Kralickova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Linked References
- L. Scarfo, A. J. Ferreri, and P. Ghia, “Chronic lymphocytic leukaemia,” Critical Reviews in Oncology/Hematology, vol. 104, pp. 169–182, 2016. View at Publisher · View at Google Scholar · View at Scopus
- F. Van Bockstaele, B. Verhasselt, and J. Philippé, “Prognostic markers in chronic lymphocytic leukemia: a comprehensive review,” Blood Reviews, vol. 23, no. 1, pp. 25–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
- C. A. Dasanu and D. T. Alexandrescu, “Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia,” Medscape General Medicine, vol. 9, no. 4, p. 35, 2007. View at Google Scholar
- S. Molica, “Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment,” Leukemia & Lymphoma, vol. 13, no. 3-4, pp. 203–214, 1994. View at Publisher · View at Google Scholar · View at Scopus
- D. Oscier, C. Dearden, E. Eren et al., “Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 159, no. 5, pp. 541–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
- A. D. Hamblin and T. J. Hamblin, “The immunodeficiency of chronic lymphocytic leukaemia,” British Medical Bulletin, vol. 87, pp. 49–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
- F. Ravandi and S. O'Brien, “Immune defects in patients with chronic lymphocytic leukemia,” Cancer Immunology, Immunotherapy, vol. 55, no. 2, pp. 197–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
- C. Dearden, “Disease-specific complications of chronic lymphocytic leukemia,” Hematology. American Society of Hematology. Education Program, vol. 2008, pp. 450–456, 2008. View at Publisher · View at Google Scholar
- V. Friman, O. Winqvist, C. Blimark, P. Langerbeins, H. Chapel, and F. Dhalla, “Secondary immunodeficiency in lymphoproliferative malignancies,” Hematological Oncology, vol. 34, no. 3, pp. 121–132, 2016. View at Publisher · View at Google Scholar · View at Scopus
- S. Sanchez-Ramon, F. Dhalla, and H. Chapel, “Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy,” Frontiers in Immunology, vol. 7, p. 317, 2016. View at Publisher · View at Google Scholar · View at Scopus
- S. Jolles, H. Chapel, and J. Litzman, “When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach,” Clinical and Experimental Immunology, vol. 188, no. 3, pp. 333–341, 2017. View at Publisher · View at Google Scholar
- F. A. Bonilla, I. Barlan, H. Chapel et al., “International Consensus Document (ICON): common variable immunodeficiency disorders,” The Journal of Allergy and Clinical Immunology. In Practice, vol. 4, no. 1, pp. 38–59, 2016. View at Publisher · View at Google Scholar · View at Scopus
- E. S. Resnick, E. L. Moshier, J. H. Godbold, and C. Cunningham-Rundles, “Morbidity and mortality in common variable immune deficiency over 4 decades,” Blood, vol. 119, no. 7, pp. 1650–1657, 2012. View at Publisher · View at Google Scholar · View at Scopus
- B. Gathmann, N. Mahlaoui, CEREDIH et al., “Clinical picture and treatment of 2212 patients with common variable immunodeficiency,” The Journal of Allergy and Clinical Immunology, vol. 134, no. 1, pp. 116–126, 2014. View at Publisher · View at Google Scholar · View at Scopus
- U. Galili, “Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits,” Immunology, vol. 140, no. 1, pp. 1–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
- H. Saleh, S. Embry, A. Nauli, S. Atyia, and G. Krishnaswamy, “Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution,” Clinical and Molecular Allergy, vol. 10, no. 1, p. 5, 2012. View at Publisher · View at Google Scholar · View at Scopus
- C. H. Chung, B. Mirakhur, E. Chan et al., “Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1109–1117, 2008. View at Publisher · View at Google Scholar · View at Scopus
- M. Hamanova, M. Chmelikova, I. Nentwich, V. Thon, and J. Lokaj, “Anti-Gal IgM, IgA and IgG natural antibodies in childhood,” Immunology Letters, vol. 164, no. 1, pp. 40–43, 2015. View at Publisher · View at Google Scholar · View at Scopus
- J. M. Bernth-Jensen, B. K. Moller, J. C. Jensenius, and S. Thiel, “Biological variation of anti-alpha Gal-antibodies studied by a novel time-resolved immunofluorometric assay,” Journal of Immunological Methods, vol. 373, no. 1-2, pp. 26–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
- M. E. Conley, L. D. Notarangelo, and A. Etzioni, “Diagnostic criteria for primary immunodeficiencies. representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies),” Clinical Immunology, vol. 93, no. 3, pp. 190–197, 1999. View at Publisher · View at Google Scholar · View at Scopus
- S. A. Parikh, J. F. Leis, K. G. Chaffee et al., “Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes,” Cancer, vol. 121, no. 17, pp. 2883–2891, 2015. View at Publisher · View at Google Scholar · View at Scopus
- A. Visentin, N. Compagno, F. Cinetto et al., “Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy,” Haematologica, vol. 100, no. 12, pp. e515–e518, 2015. View at Publisher · View at Google Scholar · View at Scopus
- H. Griffiths, J. Lea, C. Bunch, M. Lee, and H. Chapel, “Predictors of infection in chronic lymphocytic leukaemia (CLL),” Clinical and Experimental Immunology, vol. 89, no. 3, pp. 374–377, 1992. View at Publisher · View at Google Scholar
- I. Ben-Bassat, A. Many, M. Modan, C. Peretz, and B. Ramot, “Serum immunoglobulins in chronic lymphocytic leukemia,” The American Journal of the Medical Sciences, vol. 278, no. 1, pp. 4–9, 1979. View at Publisher · View at Google Scholar
- V. A. Morrison, “Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches,” Best Practice & Research. Clinical Haematology, vol. 23, pp. 145–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
- M. A. Andersen, F. J. Vojdeman, M. K. Andersen et al., “Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death,” Leukemia & Lymphoma, vol. 57, no. 7, pp. 1592–1599, 2016. View at Publisher · View at Google Scholar · View at Scopus
- L. Shvidel, T. Tadmor, A. Braester et al., “Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL study group,” European Journal of Haematology, vol. 93, no. 1, pp. 29–33, 2014. View at Publisher · View at Google Scholar · View at Scopus
- M. Pasiarski, J. Rolinski, E. Grywalska et al., “Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients – preliminary report,” PLoS One, vol. 9, no. 12, article e114966, 2014. View at Publisher · View at Google Scholar · View at Scopus
- C. Rozman, E. Montserrat, and N. Viñolas, “Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance,” Cancer, vol. 61, no. 2, pp. 279–283, 1988. View at Google Scholar
- P. D. Wadhwa and V. A. Morrison, “Infectious complications of chronic lymphocytic leukemia,” Seminars in Oncology, vol. 33, pp. 240–249, 2006. View at Google Scholar
- I. Quinti, A. Soresina, A. Guerra et al., “Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study,” Journal of Clinical Immunology, vol. 31, no. 3, pp. 315–322, 2011. View at Publisher · View at Google Scholar · View at Scopus
- F. M. Cavaliere, C. Milito, H. Martini et al., “Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency,” Journal of Clinical Immunology, vol. 33, no. 4, pp. 838–846, 2013. View at Publisher · View at Google Scholar · View at Scopus
- J. A. Freeman, K. R. Crassini, O. G. Best et al., “Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia,” Leukemia & Lymphoma, vol. 54, no. 1, pp. 99–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
- T. Svensson, M. Hoglund, and H. Cherif, “Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia,” Scandinavian Journal of Infectious Diseases, vol. 45, pp. 537–542, 2013. View at Publisher · View at Google Scholar · View at Scopus
- A. Nosari, “Infectious complications in chronic lymphocytic leukemia,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 4, no. 1, article e2012070, 2012. View at Publisher · View at Google Scholar · View at Scopus
- M. Sinisalo, J. Aittoniemi, P. Oivanen, H. Käyhty, R. M. Olander, and J. Vilpo, “Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 114, no. 1, pp. 107–110, 2001. View at Publisher · View at Google Scholar · View at Scopus
- A. Hartkamp, A. H. Mulder, G. T. Rijkers, H. van Velzen-Blad, and D. H. Biesma, “Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia,” Vaccine, vol. 19, no. 13-14, pp. 1671–1677, 2001. View at Publisher · View at Google Scholar · View at Scopus
- M. Sinisalo, J. Vilpo, M. Itälä, M. Väkeväinen, J. Taurio, and J. Aittoniemi, “Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia,” Vaccine, vol. 26, no. 1, pp. 82–87, 2007. View at Publisher · View at Google Scholar · View at Scopus
- W. Parker, K. Lundberg-Swanson, Z. E. Holzknecht et al., “Isohemagglutinins and xenoreactive antibodies: members of a distinct family of natural antibodies,” Human Immunology, vol. 45, no. 2, pp. 94–104, 1996. View at Publisher · View at Google Scholar · View at Scopus
- Z. Chovancova, M. Vlkova, J. Litzman, J. Litzman, J. Lokaj, and V. Thon, “Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination,” Vaccine, vol. 29, no. 24, pp. 4142–4150, 2011. View at Google Scholar